<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref068">
 <label>68</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Mross</surname>
   <given-names>K</given-names>
  </name>, 
  <name>
   <surname>Frost</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Steinbild</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Hedbom</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Buchert</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Fasol</surname>
   <given-names>U</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors</article-title>. 
  <source>Clin Cancer Res</source>. 
  <year>2012</year>;
  <volume>18</volume>(
  <issue>9</issue>):
  <fpage>2658</fpage>–
  <lpage>67</lpage>. Epub 2012/03/17. 
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1900</pub-id> .
  <?supplied-pmid 22421192?>
  <pub-id pub-id-type="pmid">22421192</pub-id>
 </mixed-citation>
</ref>
